The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
A novel glial cell inhibitor, low dose naltrexone, reduces pain and depression, and improves function in chronic pain: A CHOIR study
J Pain
01 April 2016
http://www.jpain.org/article/S1526-5900(16)00425-9/fulltext
Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants
J Affect Disor
15 January 2017
https://www.ncbi.nlm.nih.gov/pubmed/27736689
Could Low-Dose Naltrexone be an Effective Treatment for Hailey-Hailey Disease?
Integ Biomed Sci
19 July 2016
https://www.gratisoa.org/journals/index.php/MML/article/view/1293/957
Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness
Fatigue: Biomedicine, Health & Behavior
09 June 2018
https://www.tandfonline.com/doi/full/10.1080/21641846.2018.1477034?scroll=top&needAccess=true
Background: 30% of Gulf War veterans developed Gulf War Illness (GWI) with chronic fatigue, pain, and neuropsychological disabilities.
Naltrexone and Scopolamine Rapidly Reduce Symptoms of Major Depressive Disorder (MDD): A Double Blinded Randomized Controlled Pilot Study
Open Journal of Depression
February 2019
https://www.scirp.org/JOURNAL/PaperInformation.aspx?paperID=89841&
Potential antidepressant role of low-dose naltrexone in a rat model of chronic unpredictable mild stress
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis
J Mult Scler
September 2008
https://www.ncbi.nlm.nih.gov/pubmed/18728058
Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function
Altern Ther Health Med
05 November 2013
http://todayspractitioner.com/wp-content/uploads/2013/10/Bernard-Bihari-MD-Low-dose-Naltrexone-for-Normalizing-Immune-System-Function-athm_19_2_bihari_56_65.pdf
Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome
Med Hypotheses
April 2020
https://pubmed.ncbi.nlm.nih.gov/31954293/
Does Naltrexone Treatment Lead to Depression? Findings From a Randomized Controlled Trial in Subjects With Opioid Dependence (Abstract)
J Psychiatry Neurosci
January 2006
https://pubmed.ncbi.nlm.nih.gov/16496034/
Objective: Dysphoria and depression have been cited as side effects of the opioid antagonist naltrexone. We aimed to assess whether depressive symptoms are a clinically relevant side effect in a population receiving naltrexone as a treatment for opioid dependence.